Phosphagenics Limited ("Phosphagenics"), the Australian Stock Exchange (ASX:POH) and the London Stock Exchange’s Alternative Investment Market (AIM:PSG) listed pharmaceutical and nutraceutical company, today announces commencement of a Phase 2a clinical trial of its transdermal morphine cream, TPM-01/Morphine. The Phase 2a trial, investigating the efficacy, absorption and metabolism of morphine administered using Phosphagenics’ novel transdermal carrier TPM-01, will be conducted at the Royal Adelaide Hospital, South Australia. Preliminary results are expected during the third quarter of 2006.
